KalGene Pharmaceuticals Inc., a biotech company developing precision medicine therapeutics for effective treatment of Alzheimer’s disease, has completed second tranche of Series A, raising $[mepr-active rule=”374″ ifallowed=”hide”]#SUBSCRIBERS ONLY CONTENT Where and how did you get your news? Subscribe today to see our research on this and all other subscriber ONLY news. See what you have been missing and be informed!#[/mepr-active][mepr-active rule=”374″]1.67 million thus bringing total Series A funding to $5.84 million.[/mepr-active]
KalGene Pharmaceuticals closed its Series A in November 2017, which was led by Lumira Capital with participation from Anges Québec, Anges Québec Capital, Accel-Rx Health Sciences Accelerator and private investors.
KalGene Pharmaceuticals intends to use the funding to support the development of KalGene’s lead Alzheimer’s therapeutic candidate.
Norton Rose Fulbright Canada LLP acts as legal counsel to KalGene Pharmaceuticals.
BC/Ontario/Quebec based KalGene Pharmaceuticals is led by Dr. T. Nathan Yoganathan, President and Chief Scientific Officer, and Dr. John W. Gillard, VP of Product Development.
In 2015, KalGen raised $1.5 million from Brain Canada, CQDM, and the Ontario Brain Institute (OBI).
photo credit: KalGene Pharmaceuticals